These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35698562)

  • 1. GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma.
    Li Y; Wu J; Lu Q; Liu X; Wen J; Qi X; Liu J; Lian B; Zhang B; Sun H; Tian G
    Int J Nanomedicine; 2022; 17():2559-2575. PubMed ID: 35698562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting "substance P-hepatic stellate cells-hepatocellular carcinoma" axis.
    Li Z; Wang F; Li Y; Wang X; Lu Q; Wang D; Qi C; Li C; Li Z; Lian B; Tian G; Gao Z; Zhang B; Wu J
    Biomaterials; 2021 Sep; 276():121003. PubMed ID: 34273686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells.
    Wu J; Qi C; Wang H; Wang Q; Sun J; Dong J; Yu G; Gao Z; Zhang B; Tian G
    Front Pharmacol; 2022; 13():961788. PubMed ID: 36188590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis.
    Qi C; Wang D; Gong X; Zhou Q; Yue X; Li C; Li Z; Tian G; Zhang B; Wang Q; Wei X; Wu J
    ACS Appl Mater Interfaces; 2021 Apr; 13(14):16019-16035. PubMed ID: 33819006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N; Wu J; Wang W; Sun S; Sun M; Bian Y; Zhang H; Liu S; Yu G
    Drug Deliv Transl Res; 2024 Sep; 14(9):2386-2402. PubMed ID: 38236508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.
    Jiang H; Li ZP; Tian GX; Pan RY; Xu CM; Zhang B; Wu JL
    Int J Nanomedicine; 2019; 14():1789-1804. PubMed ID: 30880980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis.
    Wang F; Li Y; Jiang H; Li C; Li Z; Qi C; Li Z; Gao Z; Zhang B; Wu J
    Int J Nanomedicine; 2021; 16():4001-4016. PubMed ID: 34135585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Response of Multifunctional Lipid and Micelle Formulation in Hepatocellular Carcinoma.
    Wu J; Wang F; Dong J; Zhang S; Li N; Zhao H; Liu X; Gao Z; Zhang B; Tian G
    ACS Appl Mater Interfaces; 2022 Oct; 14(40):45110-45123. PubMed ID: 36167351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
    Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
    Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
    Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
    Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
    Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
    Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
    Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
    Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quiescent hepatic stellate cells induce toxicity and sensitivity to doxorubicin in cancer cells through a caspase-independent cell death pathway: Central role of apoptosis-inducing factor.
    Das D; Fayazzadeh E; Li X; Koirala N; Wadera A; Lang M; Zernic M; Panick C; Nesbitt P; McLennan G
    J Cell Physiol; 2020 Sep; 235(9):6167-6182. PubMed ID: 31975386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
    Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
    Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.